Locations:
SearchPlease join our staff as we participate or present in the following oral and poster presentations at the 2018 ASCO Annual Meeting
8:12-8:24 a.m.
S406
ORAL ABSTRACT SESSION:
Prospective clinical evaluation of blood-based tumor
mutational burden (bTMB) as a predictive biomarker
for atezolizumab (atezo) in 1L non-small cell lung
cancer (NSCLC): Interim B-F1RST results
Abstract 12001
Vamsidhar Velcheti, MD – Presenter
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients